Jefferies Cuts Price Target on Immune Design (IMDZ) Following 4Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P, Dow edge higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Immune Design (IMDZ) Misses Q4 EPS by 6c
March 10, 2016 4:13 PM ESTImmune Design (NASDAQ: IMDZ) reported Q4 EPS of ($0.60), $0.06 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $1.06 million.
For earnings history and earnings-related data on Immune Design (IMDZ) click here.
... More